Medical College of Wisconsin
Froedtert Hospital
Milwaukee, WI
Filters
Save & Share
Clear Filters
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Accepting patients
Cladribine Based Salvage Chemotherapy
A Phase II Study of the Efficacy and Pharmacogenomics of Cladribine-based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Learn more- Chemotherapy
- Steroid
- Phase 2
Accepting patients
NTX-301
A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients With MDS and AML
Learn more- DNMT1 Inhibitor
- Phase 1
Accepting patients
TCR Engineered Donor T-Cells
A Controlled Multi-Arm Ph1 Study Evaluating the Safety and Feasibility of TCR Engineered Donor TCells Targeting HA1 (TSC-100) or HA2 (TSC-101) in HLA-A0201 Positive Patients Undergoing Haploidentical Allogeneic Stem Cell Transplantation
Learn more- T Cell (Allogeneic)
- Phase 1
- Has results
Accepting patients
Vorinostat for GVHD Prevention
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Learn more- Allogeneic Stem Cell Transplant
- HDAC Inhibitor
- Phase 1/2
Accepting patients
Maintenance Ruxolitinib
Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
Learn more- JAK2 Inhibitor
- Tyrosine Kinase (TK) Inhibitor
- Maintenance
- Phase 2
Accepting patients
BGB-11417
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
Learn more- BCL-2 Inhibitor
- Phase 1/2
- Has results
Accepting patients
OPTIMIZE
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Learn more- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
MAXILUS
A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
Learn more- Erythroid Maturation Agent (EMA)
- Red Blood Cell Stimulant
- Phase 3
Accepting patients
DISC-0974
A Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Learn more- Monoclonal Antibody
- Hemojuvelin (HJV)
- Monotherapy
- Randomization
- Phase 1/2
Not yet accepting
Iadademstat
Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome
Learn more- LSD1 Inhibitor
- Phase 1